Last 12 months
Inside the activity.
4 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 1 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2019 Filed Feb 25, 2019 22:42 UTC |
Walsh DesExecutive Vice Chairman
|
GrantStock Appreciation Rights · Derivative | 25,508 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013130 · doc4.xml · derivative · entry 2 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,016 Underlying: Common Stock · 25,508 shares Expires 2027-02-27 F2 · shares: On February 27, 2017, the Reporting Person was granted an award of 127,542 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 25,508 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:42 UTC |
Walsh DesExecutive Vice Chairman
|
GrantStock Appreciation Rights · Derivative | 72,798 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013130 · doc4.xml · derivative · entry 1 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,330 Underlying: Common Stock · 72,798 shares Expires 2026-05-09 F1 · shares: On May 9, 2016, the Reporting Person was granted an award of 121,330 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 72,798 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:39 UTC |
PEZZULLO DAVIDChief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 9,180 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013121 · doc4.xml · derivative · entry 3 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 Underlying: Common Stock · 9,180 shares Expires 2027-02-27 F4 · shares: On February 27, 2017, the Reporting Person was granted an award of 45,902 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 9,180 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:39 UTC |
PEZZULLO DAVIDChief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 26,200 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013121 · doc4.xml · derivative · entry 2 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,668 Underlying: Common Stock · 26,200 shares Expires 2026-05-09 F3 · shares: On May 9, 2016, the Reporting Person was granted an award of 43,668 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 26,200 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:32 UTC |
LEVY ROBERTEVP, The Americas
|
GrantStock Appreciation Rights · Derivative | 9,180 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013102 · doc4.xml · derivative · entry 3 LEVY ROBERT · CIK 0001311283 · EVP, The Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,360 Underlying: Common Stock · 9,180 shares Expires 2027-02-27 F3 · shares: On February 27, 2017, the Reporting Person was granted an award of 45,902 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 9,180 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:32 UTC |
LEVY ROBERTEVP, The Americas
|
GrantStock Appreciation Rights · Derivative | 26,200 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013102 · doc4.xml · derivative · entry 2 LEVY ROBERT · CIK 0001311283 · EVP, The Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,668 Underlying: Common Stock · 26,200 shares Expires 2026-05-09 F2 · shares: On May 9, 2016, the Reporting Person was granted an award of 43,668 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 26,200 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:26 UTC |
JOHNSON MICHAELDirector · Chairman and CEO
|
GrantStock Appreciation Rights · Derivative | 35,310 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013092 · doc4.xml · derivative · entry 2 JOHNSON MICHAEL · CIK 0001311173 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,620 Underlying: Common Stock · 35,310 shares Expires 2027-02-27 F2 · shares: On February 27, 2017, the Reporting Person was granted an award of 176,552 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 35,310 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:26 UTC |
JOHNSON MICHAELDirector · Chairman and CEO
|
GrantStock Appreciation Rights · Derivative | 201,544 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013092 · doc4.xml · derivative · entry 1 JOHNSON MICHAEL · CIK 0001311173 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,908 Underlying: Common Stock · 201,544 shares Expires 2026-05-09 F1 · shares: On May 9, 2016, the Reporting Person was granted an award of 335,908 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 201,544 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:19 UTC |
Hoffman Alan LEVP, Global Corporate Affairs
|
GrantStock Appreciation Rights · Derivative | 9,180 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013087 · doc4.xml · derivative · entry 3 Hoffman Alan L · CIK 0001624527 · EVP, Global Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,180 Underlying: Common Stock · 9,180 shares Expires 2027-02-27 F3 · shares: On February 27, 2017, the Reporting Person was granted an award of 45,902 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 9,180 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:19 UTC |
Hoffman Alan LEVP, Global Corporate Affairs
|
GrantStock Appreciation Rights · Derivative | 26,200 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013087 · doc4.xml · derivative · entry 2 Hoffman Alan L · CIK 0001624527 · EVP, Global Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,200 Underlying: Common Stock · 26,200 shares Expires 2026-05-09 F2 · shares: On May 9, 2016, the Reporting Person was granted an award of 43,668 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 26,200 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:12 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantCommon Stock · Derivative | 7,062 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013074 · doc4.xml · derivative · entry 4 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,124 Underlying: Common Stock · 7,062 shares Expires 2027-02-27 F4 · shares: On February 27, 2017, the Reporting Person was granted an award of 35,310 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 7,062 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:12 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantCommon Stock · Derivative | 20,154 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013074 · doc4.xml · derivative · entry 3 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,872 Underlying: Common Stock · 20,154 shares Expires 2026-05-09 F3 · shares: On May 9, 2016, the Reporting Person was granted an award of 33,590 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 20,154 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:06 UTC |
DeSimone JohnCo-President
|
GrantStock Appreciation Rights · Derivative | 24,506 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013050 · doc4.xml · derivative · entry 3 DeSimone John · CIK 0001463405 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,012 Underlying: Common Stock · 0 shares Expires 2027-02-27 F3 · shares: On February 27, 2017, the Reporting Person was granted an award of 122,528 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 24,506 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:06 UTC |
DeSimone JohnCo-President
|
GrantStock Appreciation Rights · Derivative | 69,936 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013050 · doc4.xml · derivative · entry 2 DeSimone John · CIK 0001463405 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,560 Underlying: Common Stock · 0 shares Expires 2026-05-09 F2 · shares: On May 9, 2016, the Reporting Person was granted an award of 116,560 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 69,936 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:00 UTC |
Chiu Shin-Shing BoscoEVP, Chief Financial Officer
|
GrantStock Appreciation Rights · Derivative | 3,248 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-19-013038 · doc4.xml · derivative · entry 3 Chiu Shin-Shing Bosco · CIK 0001504597 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,496 Underlying: Common Stock · 3,248 shares Expires 2027-02-27 F4 · shares: On February 27, 2017, the Reporting Person was granted an award of 16,242 PSARs, which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2017, 2018 and 2019. As the performance criteria for 2018 has been satisfied, 3,248 PSARs will vest on February 27, 2019, subject to continued service through each applicable date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 22:00 UTC |
Chiu Shin-Shing BoscoEVP, Chief Financial Officer
|
GrantStock Appreciation Rights · Derivative | 9,270 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-19-013038 · doc4.xml · derivative · entry 2 Chiu Shin-Shing Bosco · CIK 0001504597 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,450 Underlying: Common Stock · 9,270 shares Expires 2026-05-09 F3 · shares: On May 9, 2016, the Reporting Person was granted an award of 15,450 performance stock appreciation rights ("PSARs"), which number reflects the Issuer's 2-for-1 stock split on May 14, 2018. The amount and timing of the vesting of these PSARs is dependent upon achievement by the Issuer of certain performance criteria for each of fiscal 2016, 2017 and 2018. As the performance criteria for 2018 has been satisfied, 9,270 PSARs will vest on May 9, 2019, subject to continued service through each applicable date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:44 UTC |
Wang Henry CEVP, General Counsel
|
GrantCommon Stock | 2,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013132 · doc4.xml · nonDerivative · entry 1 Wang Henry C · CIK 0001738879 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,659 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. F2 · balance_after: Reflects 1,882 additional shares of common stock, after giving effect to the Issuer's 2-for-1 stock split on May 14, 2018. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:39 UTC |
PEZZULLO DAVIDChief Operating Officer
|
GrantCommon Stock | 5,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013121 · doc4.xml · nonDerivative · entry 1 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,554 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. F2 · balance_after: Balance reflects shares purchased through the Issuer's Herbalife Ltd. Employee Stock Purchase Plan following a reconciliation to the Reporting Person's account records. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:32 UTC |
LEVY ROBERTEVP, The Americas
|
GrantCommon Stock | 2,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013102 · doc4.xml · nonDerivative · entry 1 LEVY ROBERT · CIK 0001311283 · EVP, The Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,883 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:19 UTC |
Hoffman Alan LEVP, Global Corporate Affairs
|
GrantCommon Stock | 2,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013087 · doc4.xml · nonDerivative · entry 1 Hoffman Alan L · CIK 0001624527 · EVP, Global Corporate Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,518 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:12 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantCommon Stock | 6,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013074 · doc4.xml · nonDerivative · entry 2 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 8,836 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:12 UTC |
Hienrich EdiSVP/Managing Director EMEA
|
GrantCommon Stock | 8,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013074 · doc4.xml · nonDerivative · entry 1 Hienrich Edi · CIK 0001472187 · SVP/Managing Director EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,395 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. F2 · balance_after: Reflects 7,244 additional shares of common stock, after giving effect to the Issuer's 2-for-1 stock split on May 14, 2018. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:10 UTC |
Harms ThomasSVP, China & APAC
|
GrantCommon Stock | 7,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013068 · doc4.xml · nonDerivative · entry 1 Harms Thomas · CIK 0001713357 · SVP, China & APAC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,394 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. F2 · balance_after: Reflects 4,634 additional shares of common stock, after giving effect to the Issuer's 2-for-1 stock split on May 14, 2018. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:06 UTC |
DeSimone JohnCo-President
|
GrantCommon Stock | 5,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013050 · doc4.xml · nonDerivative · entry 1 DeSimone John · CIK 0001463405 · Co-President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,026 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 22:00 UTC |
Chiu Shin-Shing BoscoEVP, Chief Financial Officer
|
GrantCommon Stock | 2,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013038 · doc4.xml · nonDerivative · entry 1 Chiu Shin-Shing Bosco · CIK 0001504597 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,523 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. F2 · balance_after: Reflects 11,314 additional shares of common stock, after giving effect to the Issuer's 2-for-1 stock split on May 14, 2018. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 21:54 UTC |
Amezquita AlexanderSVP, Finance, Strategy and IR
|
GrantCommon Stock | 4,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013025 · doc4.xml · nonDerivative · entry 1 Amezquita Alexander · CIK 0001721325 · SVP, Finance, Strategy and IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,608 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 21:51 UTC |
Agwunobi John OCo-President/Chief H&N Officer
|
GrantCommon Stock | 5,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013021 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Co-President/Chief H&N Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,115 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 21, 2020, 20% on February 21, 2021, and 60% on February 21, 2022, subject to continued service through each applicable date. F2 · balance_after: Reflects 3,707 additional shares of common stock, after giving effect to the Issuer's 2-for-1 stock split on May 14, 2018. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:19 UTC |
Walsh DesExecutive Vice Chairman
|
Exercise / conversionStock Appreciation Rights · Derivative | 300,000 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001209191-18-058574 · doc4.xml · derivative · entry 4 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 141,765 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 139,405 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. F4 · derivative.underlying_shares: These SARS were previously reported as covering 150,000 shares at an exercise price of $6.82 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:19 UTC |
Walsh DesExecutive Vice Chairman
|
Tax withholdingCommon Stock | 139,405 | $54.33 | $7,573,873.65 |
DisclosureSEC source: 0001209191-18-058574 · doc4.xml · nonDerivative · entry 3 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,943 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 141,765 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 139,405 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:19 UTC |
Walsh DesExecutive Vice Chairman
|
Disposition to issuerCommon Stock | 18,830 | $54.33 | $1,023,033.90 |
DisclosureSEC source: 0001209191-18-058574 · doc4.xml · nonDerivative · entry 2 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,348 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 141,765 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 139,405 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 22:19 UTC |
Walsh DesExecutive Vice Chairman
|
Exercise / conversionCommon Stock | 300,000 | $3.41 | $1,023,000.00 |
DisclosureSEC source: 0001209191-18-058574 · doc4.xml · nonDerivative · entry 1 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 141,765 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 139,405 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. F3 · balance_after: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 159,089 additional shares of common stock. Read SEC document |
| November 12, 2018 Filed Nov 21, 2018 21:30 UTC Amendment |
Walsh DesExecutive Vice Chairman
|
Exercise / conversionStock Appreciation Rights · Derivative | 300,000 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0001209191-18-059725 · doc4a.xml · derivative · entry 4 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 133,133 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 148,037 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. F4 · derivative.underlying_shares: These SARS were previously reported as covering 150,000 shares at an exercise price of $6.82 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| November 12, 2018 Filed Nov 21, 2018 21:30 UTC Amendment |
Walsh DesExecutive Vice Chairman
|
Tax withholdingCommon Stock | 148,037 | $54.33 | $8,042,850.21 |
DisclosureSEC source: 0001209191-18-059725 · doc4a.xml · nonDerivative · entry 3 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,311 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 133,133 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 148,037 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. Read SEC document |
| November 12, 2018 Filed Nov 21, 2018 21:30 UTC Amendment |
Walsh DesExecutive Vice Chairman
|
Disposition to issuerCommon Stock | 18,830 | $54.33 | $1,023,033.90 |
DisclosureSEC source: 0001209191-18-059725 · doc4a.xml · nonDerivative · entry 2 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,348 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 133,133 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 148,037 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. Read SEC document |
| November 12, 2018 Filed Nov 21, 2018 21:30 UTC Amendment |
Walsh DesExecutive Vice Chairman
|
Exercise / conversionCommon Stock | 300,000 | $3.41 | $1,023,000.00 |
DisclosureSEC source: 0001209191-18-059725 · doc4a.xml · nonDerivative · entry 1 Walsh Des · CIK 0001373040 · Executive Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · kind: The reporting person received 133,133 shares of common stock upon the net exercise of 300,000 stock appreciation rights ("SARS"). The reporting person forfeited 18,830 shares of common stock underlying the SARS in payment of the exercise price and 148,037 shares of common stock underlying the SARS to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on November 12, 2018 of $54.33. The reporting person did not sell any shares received from this net exercise of SARS. F3 · balance_after: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 159,089 additional shares of common stock. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 21:49 UTC |
Amezquita AlexanderSVP, Finance & Strat. Planning
|
Tax withholdingCommon Stock | 831 | $55.19 | $45,862.89 |
DisclosureSEC source: 0001209191-18-057758 · doc4.xml · nonDerivative · entry 1 Amezquita Alexander · CIK 0001721325 · SVP, Finance & Strat. Planning 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,511 F1 · kind: The reporting person was previously granted restricted stock units on November 6, 2017, a portion of which vested on November 6, 2018. The reporting person forfeited 831 shares of the Issuer's common stock to satisfy the tax withholding obligation resulting from the vest, using the closing stock price on November 6, 2018 of $55.19. F2 · balance_after: On May 14, 2018, the common stock of Herbalife Nutrition Ltd. split 2-for-1, resulting in the reporting person's acquisition of 8,671 additional shares of common stock. Read SEC document |
| September 18, 2018 Filed Sep 18, 2018 20:33 UTC |
PEZZULLO DAVIDChief Operating Officer
|
SaleCommon Stock | 66,805 | $55.12 | $3,682,291.60 |
DisclosureSEC source: 0001209191-18-051478 · doc4.xml · nonDerivative · entry 11 PEZZULLO DAVID · CIK 0001311282 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,940 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2018. F7 · price: This transaction was executed in multiple trades at prices ranging from $54.65 to $55.59. The price reported reflects the weighted average sale price of $55.12. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 25,508 | $0.00 Strike: $28.60 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 40 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,034 Underlying: Common Stock · 25,508 shares Expires 2027-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F22 · derivative.exercise_date: On February 27, 2017, the reporting person was granted 63,771 SARs. These SARs vested 20% on February 27, 2018 and 20% will vest on February 27, 2019 and 60% will vest on February 27, 2020. F23 · derivative.underlying_shares: These SARS were previously reported as covering 63,771 shares at an exercise price of $57.19 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 48,532 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 39 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,798 Underlying: Common Stock · 48,532 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · kind: The reporting person received 10,008 shares of common stock upon the net exercise of the 48,532 SARS. The reporting person forfeited 27,526 shares of common stock underlying the SARS in payment of the exercise price and 10,998 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F20 · derivative.exercise_date: On May 9, 2016, the reporting person was granted 60,665 SARs. These SARs vested 20% each on May 9, 2017 and May 9, 2018, and 60% will vest on May 9, 2019. F21 · derivative.underlying_shares: These SARS were previously reported as covering 60,665 shares at an exercise price of $62.51 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 166,500 | $0.00 Strike: $23.90 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 38 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,500 shares Expires 2025-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · kind: The reporting person received 44,927 shares of common stock upon the net exercise of the 166,500 SARS. The reporting person forfeited 72,209 shares of common stock underlying the SARS in payment of the exercise price and 49,364 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F19 · derivative.underlying_shares: These SARS were previously reported as covering 83,250 shares at an exercise price of $47.80 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 244,698 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 37 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 244,698 shares Expires 2025-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: The reporting person received 84,393 shares of common stock upon the net exercise of the 244,698 SARS. The reporting person forfeited 67,582 shares of common stock underlying the SARS in payment of the exercise price and 92,723 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F18 · derivative.underlying_shares: These SARS were previously reported as covering 122,349 shares at an exercise price of $30.44 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 166,804 | $0.00 Strike: $29.99 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 36 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,804 shares Expires 2024-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: The reporting person received 36,226 shares of common stock upon the net exercise of the 166,804 SARS. The reporting person forfeited 90,774 shares of common stock underlying the SARS in payment of the exercise price and 39,804 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F17 · derivative.underlying_shares: These SARS were previously reported as covering 83,402 shares at an exercise price of $59.98 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 109,322 | $0.00 Strike: $39.79 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 35 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,322 shares Expires 2023-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The reporting person received 14,477 shares of common stock upon the net exercise of the 109,322 SARS. The reporting person forfeited 78,934 shares of common stock underlying the SARS in payment of the exercise price and 15,911 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F16 · derivative.underlying_shares: These SARS were previously reported as covering 54,661 shares at an exercise price of $79.58 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 236,852 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 34 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 236,852 shares Expires 2022-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The reporting person received 66,996 shares of common stock upon the net exercise of the 236,852 SARS. The reporting person forfeited 96,250 shares of common stock underlying the SARS in payment of the exercise price and 73,606 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F15 · derivative.underlying_shares: These SARS were previously reported as covering 118,426 shares at an exercise price of $44.79 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 116,018 | $0.00 Strike: $26.65 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 33 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,018 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The reporting person received 28,553 shares of common stock upon the net exercise of the 116,018 SARS. The reporting person forfeited 56,094 shares of common stock underlying the SARS in payment of the exercise price and 31,371 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F14 · derivative.underlying_shares: These SARS were previously reported as covering 58,009 shares at an exercise price of $53.29 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 106,186 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 32 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,186 shares Expires 2020-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reporting person received 40,066 shares of common stock upon the net exercise of the 106,186 SARS. The reporting person forfeited 22,101 shares of common stock underlying the SARS in payment of the exercise price and 44,019 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F13 · derivative.underlying_shares: These SARS were previously reported as covering 66,366 shares at an exercise price of $22.94 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 240,000 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · derivative · entry 31 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2020-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person received 92,918 shares of common stock upon the net exercise of the 240,000 Stock Appreciation Rights ("SARS"). The reporting person forfeited 44,998 shares of common stock underlying the SARS in payment of the exercise price and 102,084 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. F12 · derivative.underlying_shares: These SARS were previously reported as covering 120,000 shares at an exercise price of $20.67 per share, but were adjusted to reflect the stock split that occurred on May 14, 2018. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Tax withholdingCommon Stock | 6,425 | $55.11 | $354,081.75 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 30 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,213 F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Disposition to issuerCommon Stock | 13,236 | $55.11 | $729,435.96 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 29 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,638 F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:36 UTC |
GOUDIS RICHARDChief Executive Officer
|
Exercise / conversionCommon Stock | 25,508 | $28.60 | $729,528.80 |
DisclosureSEC source: 0001209191-18-051483 · doc4.xml · nonDerivative · entry 28 GOUDIS RICHARD · CIK 0001311175 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 880,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · kind: The reporting person received 5,847 shares of common stock upon the net exercise of the 25,508 SARS. The reporting person forfeited 13,236 shares of common stock underlying the SARS in payment of the exercise price and 6,425 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on September 17, 2018 of $55.11. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.